Mostrar el registro sencillo

dc.contributor.authorSantamaría Aguirre, Javier
dc.contributor.authorJacho, Daniela
dc.contributor.authorMéndez, Miguel A.
dc.contributor.authorPoveda, Ana
dc.contributor.authorCarrión, Javier
dc.contributor.authorLópez Fanarraga, Mónica 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-04-08T14:43:58Z
dc.date.available2024-04-08T14:43:58Z
dc.date.issued2024
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/10902/32510
dc.description.abstractLeishmaniasis, a zoonotic parasitic disease transmitted by infected sandflies, impacts nearly 1 million people yearly and is endemic in many countries across Asia, Africa, the Americas, and the Mediterranean; despite this, it remains a neglected disease with limited effective treatments, particularly in impoverished communities with limited access to healthcare. This study aims to repurpose approved drugs for an affordable leishmaniasis treatment. After the screening of potential drug candidates by reviewing databases and utilizing molecular docking analysis, delamanid was chosen to be incorporated into solid lipid nanoparticles (SLNPs). Both in cellulo and in vivo tests confirmed the successful payload release within macrophages and through the epidermis following topical application on murine skin. The evaluation of macrophages infected with L. infantum amastigotes showed that the encapsulated delamanid exhibited greater leishmanicidal activity compared with the free drug. The process of encapsulating delamanid in SLNPs, as demonstrated in this study, places a strong emphasis on employing minimal technology, ensuring energy efficiency, cost-effectiveness, and reproducibility. It enables consistent, low-cost production of nanomedicines, even on a small scale, offering a promising step toward more accessible and effective leishmaniasis treatments.es_ES
dc.format.extent14 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePharmaceutics, 2024, 16(1), 41es_ES
dc.subject.otherZoonosises_ES
dc.subject.otherTrypanosomatides_ES
dc.subject.otherNanomedicinees_ES
dc.subject.otherNeglectedes_ES
dc.subject.otherFluoroquinolonees_ES
dc.subject.otherBenzimidazoleses_ES
dc.titleSolid lipid nanoparticles enhancing the leishmanicidal activity of delamanides_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/pharmaceutics16010041
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International